Browse the latest research summaries in the field of pharmacology for spinal cord injury patients and caregivers.
Showing 501-510 of 525 results
International Journal of Surgery, 2025 • June 24, 2024
This prospective, double-blind, randomized controlled study evaluated the safety and efficacy of intrawound vancomycin powder in preventing surgical site infections (SSIs) after posterior lumbar inter...
KEY FINDING: The study found an 87.5% decrease in the surgical site infection (SSI) rate in the vancomycin group compared to the control group.
Neural Regeneration Research, 2023 • May 1, 2023
Spinal cord injury results in the loss of functional mobility, sensations, and neuromuscular and skeletal function. Injury can lead to apoptosis of the neurons and degradation of oligodendrocytes caus...
KEY FINDING: Clemastine enhances oligodendrocyte differentiation and myelination, which helps to delay axonal degeneration and promote motor function recovery in rat SCI models.
Neural Regen Res, 2025 • May 1, 2025
Spinal cord regeneration is a complex physiological process, and no optimal treatment has yet been developed for fully repairing the spinal cord. Theoretically, combinatorial strategies have the highe...
KEY FINDING: The synergistic effect between anti-Nogo-A antibody and chondroitinase ABC (ChABC) enzyme resulted in superior outcomes, leading to enhanced sprouting and axon regeneration.
iScience, 2023 • January 20, 2023
This study investigates the metabolic mechanisms underlying artemisinin resistance (ART-R) in Plasmodium falciparum, focusing on the role of PfKelch13 mutations and ring-stage growth arrest. The resea...
KEY FINDING: PfKelch13 mutant parasite lines exhibit reduced susceptibility to DHA and prolonged ring stage.
International Journal of Spine Surgery, 2022 • October 12, 2022
This systematic review summarizes the existing literature regarding the use of amniotic membrane preparations, treatment regimens, and indications within spinal surgery. The review of reported studies...
KEY FINDING: Amnion products show promising effects in reducing epidural adhesions and scar tissue after spine surgery.
J Spinal Cord Med, 2008 • January 1, 2008
This retrospective cohort study compared the effectiveness of dalteparin and low-dose unfractionated heparin (LDUH) for preventing clinically evident venous thromboembolism (VTE) in patients with acut...
KEY FINDING: There was no statistically significant difference in the incidence of VTE between patients receiving dalteparin and those receiving LDUH.
Clinical Pharmacology in Drug Development, 2021 • March 1, 2021
This study reports the first clinical experience with MW189, a novel CNS-penetrant small molecule that selectively suppresses injury- and disease-induced glial proinflammatory cytokine overproduction....
KEY FINDING: MW189 was safe and well tolerated in single and multiple doses up to 0.25 mg/kg, with infusion-site reactions being the most common adverse event.
Spinal Cord Series and Cases, 2019 • March 19, 2019
The case report highlights the occurrence of gluteal hematomas in two patients with chronic spinal cord injury who were receiving prophylactic enoxaparin for venous thromboembolism (VTE). The authors ...
KEY FINDING: Two patients with chronic SCI developed gluteal hematomas while on prophylactic enoxaparin, requiring surgical intervention and delaying rehabilitation.
Neurochemical Research, 2025 • November 30, 2024
The study developed a novel slow-release nanoparticle estrogen (SNP-E2) delivery system that provides sustained release of E2 in the injured spinal cord without systemic exposure. Delivery of E2 via S...
KEY FINDING: SNP-E2 delivery reduced inflammation and gliosis, and induced microglial differentiation of M1 to M2 in rats after SCI.
International Journal of Molecular Sciences, 2022 • March 15, 2022
This review highlights the potential of sovateltide, a selective ETBRs agonist, as a therapeutic candidate for neurological disorders. Preclinical and clinical studies suggest its safety and efficacy ...
KEY FINDING: Sovateltide has shown promise in preclinical studies for treating cerebral stroke, Alzheimer's disease, spinal cord injury, and neonatal hypoxic-ischemic encephalopathy by promoting neuroprotection and neuroregeneration.